Pfizer (PFE) Announces FDA Acceptance for Priority Review of sBLA for 20vPnC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Pfizer (PFE) Announces FDA Acceptance for Priority Review of sBLA for 20vPnC
January 10, 2023 1:43 PM EST
Pfizer (NYSE: PFE) management presented at an investor conference yesterday its Chief Executive Albert Bourla said to have reiterated plans for shaping Pfizer post-Covid.
Following the Pfizer presentation, Credit Suisse analyst Trung Huynh told investors in a note that Pfizer focused on the non-Covid side of the business.
"For the non-COVID sales, Dr. Bourla reiterated its 2020-25 mid-term guide of +6% and also first-time longer-term 2025-30 guidance of 6-10%, which comes in ahead of consensus expectations," wrote Huynh, who maintained... More
January 6, 2023 10:08 AM EST
In a note to clients Friday, Morgan Stanley analyst Terence Flynn said the firm sees downside risk to Pfizer's (NYSE: PFE) EPS guidance.
The analyst explained that Pfizer will provide 1st time 2023 guidance in conjunction with fourth-quarter earnings on January 31 and the company previously noted that they plan to... More
